Recent research have focused on the overlap of glucagon-like peptide-1|GIP|glucagon receptor activator therapies and dopaminergic signaling. While GCGR agonists are widely employed for managing type 2 diabetes mellitus, their unexpected effects on reward circuits, specifically mediated by dopamin